1차 출처 기록
결정급탑라인 결과
Annexon: ARCHER II 3상 vonaprument GA 탑라인 데이터, 2026년 4분기 예상
회사는 지도상 위축(GA) 치료제 vonaprument의 ARCHER II 3상 임상시험 탑라인 데이터가 2026년 4분기로 예정됐다고 발표했다. 이번 결과는 해당 자산의 주요 규제·임상 이정표이며, 글로벌 허가 신청을 뒷받침할 예정이다.
핵심 사실
출처 발췌
EX-99.1 2 annx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré Syndrome (GBS); Biologics License Application (BLA) Submission with U.S./European FORWARD Data Expected in 2026 Proof-of-Concept (POC) Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $225 Million as of M